The company organizes events and manages media activities, including film production and distribution, primarily for the Indian entertainment market.
The company lacks a durable competitive advantage, as evidenced by extremely low returns on capital (ROCE 2.8%) and a recent pivot from pharmaceutical trading to media services. High revenue growth appears driven by a low base and recent acquisitions rather than organic pricing power or network effects.
Management has focused on aggressive expansion through preferential share warrants and the acquisition of multiple subsidiaries like Sakshi Barter and Navkar Events. However, the resulting returns on equity and capital remain negligible, suggesting value destruction or inefficient use of shareholder funds.
The company's aggressive pivot from pharmaceutical trading to media services proved to be a value-destroying distraction, as the capital raised through preferential warrants was squandered on low-return subsidiaries. The disconnect between reported accounting profits and negative cash conversion eventually forced a liquidity crisis, while the persistent failure to adhere to regulatory disclosure requirements led to severe exchange-mandated penalties or delisting. Without a core competency or organic pricing power, the business model collapsed under the weight of its own administrative incompetence and lack of operational focus.
RichFakir rates JOJO Ltd's business quality as poor — 22/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, JOJO Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on JOJO Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of JOJO Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →